This compound is a critical phosphoramidite reagent for oligonucleotide synthesis, specifically designed for 5'-end phosphorylation of DNA/RNA fragments. It introduces a phosphate group at the 5'-terminus during solid-phase synthesis, essential for constructing antisense oligonucleotides, siRNA, and aptamers used in nucleic acid therapeutics. The DMT (dimethoxytrityl) protecting group ensures selective 5'-hydroxyl activation, while the cyanoethyl and diisopropylamino groups enable efficient coupling and deprotection under standard phosphoramidite chemistry conditions. It is widely used in GMP-compliant manufacturing of small nucleic acid drugs, supporting late-stage drug development and commercial production. Additionally, it serves as a key building block in academic research for studying nucleic acid structure-function relationships and developing novel gene-editing tools.

GHS Classification: GHS07 (Warning) Hazard Statements: H302 (Harmful if swallowed); H315 (Causes skin irritation); H319 (Causes serious eye irritation); H335 (May cause respiratory irritation) Precautionary Statements: P261, P270, P280, P302+P352, P305+P351+P338 This phosphoramidite has moderate acute toxicity (oral LD50 500–5000 mg/kg in rats). Skin contact may cause redness, itching, or dermatitis; eye contact can lead to severe irritation, tearing, or corneal damage. Inhalation of vapors/aerosols may trigger respiratory tract irritation, coughing, or shortness of breath. No evidence of carcinogenicity or mutagenicity is reported, but prolonged exposure should be minimized. Handle in a fume hood with nitrile gloves, safety goggles, and a respirator. In case of eye contact, rinse with water for 15 minutes. Store under inert gas away from moisture, acids, and oxidizers. Dispose of waste per local hazardous waste regulations.